ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. for the period between March 17, 2023, and November 17, 2024, due to alleged misleading statements regarding the company's financial health and product candidates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Sana Biotechnology made false and misleading statements about its financial capacity and the potential of its product candidates [5]. - Specific allegations include that Sana was at significant risk of insufficient funds to maintain operations and that key product candidates were less promising than represented [5]. - The lawsuit asserts that the defendants overstated Sana's ability to maintain operations and advance product candidates, leading to investor damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Sana securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].